The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives Publisher Pubmed

Ashrafizadeh M¹ ; Farhood B² ; Eleojo Musa A³ ; Taeb S⁴ ; Najafi M⁵

Source: International Immunopharmacology Published:2020

Abstract

Tumor microenvironment (TME) includes a wide range of cell types including cancer cells, cells which are involved in stromal structure and immune cells (tumor suppressor and tumor promoting cells). These cells have several interactions with each other that are mainly regulated via the release of intercellular mediators. Radiotherapy can modulate these interactions via shifting secretions into inflammatory or anti-inflammatory responses. Radiotherapy also can trigger resistance of cancer (stem) cells via activation of stromal cells. The main mechanisms of tumor resistance to radiotherapy is the exhaustion of anti-tumor immunity via suppression of CD4+ T cells and apoptosis of cytotoxic CD8+ T lymphocytes (CTLs). Cancer-associated fibroblasts (CAFs), mesenchymal-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) are the main suppressor of anti-tumor immunity via the release of several chemokines, cytokines and immune suppressors. In this review, we explain the main cellular and molecular interactions and secretions in TME following radiotherapy. Furthermore, the main signaling pathways and intercellular connections that can be targeted to improve therapeutic efficiency of radiotherapy will be discussed. © 2020 Elsevier B.V.

Related Docs

View other Related Docs

1. Targets for Improving Tumor Response to Radiotherapy, International Immunopharmacology (2019)

2. Boosting Immune System Against Cancer by Resveratrol, Phytotherapy Research (2021)

3. Damage-Associated Molecular Patterns in Tumor Radiotherapy, International Immunopharmacology (2020)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (2)

Elahe Motevaseli (2)

Other Related Docs

4. Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy, Current Cancer Drug Targets (2022)

5. Tumor Immunology, Clinical Immunology (2022)

6. Radiotherapy Combination: Insight From Tumor Immune Microenvironment (Time), Avicenna Journal of Medical Biotechnology (2023)

7. Radiation Dose and Schedule Influence the Abscopal Effect in a Bilateral Murine Ct26 Tumor Model, International Immunopharmacology (2022)

8. Immunoregulation by Resveratrol; Implications for Normal Tissue Protection and Tumour Suppression, Clinical and Experimental Pharmacology and Physiology (2023)

9. Abscopal Effect in Radioimmunotherapy, International Immunopharmacology (2020)

10. Tgf-Β in Radiotherapy: Mechanisms of Tumor Resistance and Normal Tissues Injury, Pharmacological Research (2020)

11. Natural Killer Cell–Based Immunotherapy: From Transplantation Toward Targeting Cancer Stem Cells, Journal of Cellular Physiology (2018)

12. Regulation of Cell Death Mechanisms by Melatonin: Implications in Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry (2022)

13. Cancer-Associated Mesenchymal Stem/Stromal Cells: Role in Progression and Potential Targets for Therapeutic Approaches, Frontiers in Immunology (2023)

14. Cancer-Associated Fibroblasts (Cafs) and Tumor-Associated Macrophages (Tams); Where Do They Stand in Tumorigenesis and How They Can Change the Face of Cancer Therapy?, European Journal of Pharmacology (2022)

15. Modulation of the Immune System by Melatonin; Implications for Cancer Therapy, International Immunopharmacology (2022)

16. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)

17. An Update to Experimental and Clinical Aspects of Tumor-Associated Macrophages in Cancer Development: Hopes and Pitfalls, Clinical and Experimental Medicine (2024)

18. Modulation of Apoptosis by Melatonin for Improving Cancer Treatment Efficiency: An Updated Review, Life Sciences (2019)

19. Metformin As a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization, Current Clinical Pharmacology (2019)

20. Nf-Κb Targeting for Overcoming Tumor Resistance and Normal Tissues Toxicity, Journal of Cellular Physiology (2019)

Style	Citing Format
MLA	Ashrafizadeh M, et al.. "The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives." International Immunopharmacology, vol. 87, no. , 2020, pp. -.
APA	Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Najafi M (2020). The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives. International Immunopharmacology, 87(), -.
Chicago	Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Najafi M. "The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives." International Immunopharmacology 87, no. (2020): -.
Harvard	Ashrafizadeh M et al. (2020) 'The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives', International Immunopharmacology, 87(), pp. -.
Vancouver	Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Najafi M. The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives. International Immunopharmacology. 2020;87():-.
BibTex	@article{ author = {Ashrafizadeh M and Farhood B and Eleojo Musa A and Taeb S and Najafi M}, title = {The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives}, journal = {International Immunopharmacology}, volume = {87}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Ashrafizadeh M AU - Farhood B AU - Eleojo Musa A AU - Taeb S AU - Najafi M TI - The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives JO - International Immunopharmacology VL - 87 IS - SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Abstract